Fatourechi Vahab
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Mayo Clin Proc. 2009;84(1):65-71. doi: 10.4065/84.1.65.
Subclinical hypothyroidism (SCH), also called mild thyroid failure, is diagnosed when peripheral thyroid hormone levels are within normal reference laboratory range but serum thyroid-stimulating hormone (TSH) levels are mildly elevated. This condition occurs in 3% to 8% of the general population. It is more common in women than men, and its prevalence increases with age. Of patients with SCH, 80% have a serum TSH of less than 10 mIU/L. The most important implication of SCH is high likelihood of progression to clinical hypothyroidism. The possibility that it is a cardiovascular risk factor has been a subject of debate. Large-scale randomized studies are needed for evidence-based recommendations regarding screening for mild thyroid failure and levothyroxine therapy for this condition. Currently, the practical approach is routine levothyroxine therapy for persons with a persistent serum TSH of more than 10.0 mIU/L and individualized therapy for those with a TSH of less than 10.0 mIU/L.
亚临床甲状腺功能减退症(SCH),也称为轻度甲状腺功能衰竭,是在周围甲状腺激素水平处于正常参考实验室范围内,但血清促甲状腺激素(TSH)水平轻度升高时被诊断出来的。这种情况在普通人群中的发生率为3%至8%。女性比男性更常见,且其患病率随年龄增长而增加。在SCH患者中,80%的血清TSH低于10 mIU/L。SCH最重要的影响是进展为临床甲状腺功能减退症的可能性很高。它是否为心血管危险因素一直存在争议。需要进行大规模随机研究,以获得关于轻度甲状腺功能衰竭筛查和左甲状腺素治疗的循证医学建议。目前,实际的方法是对血清TSH持续高于10.0 mIU/L的患者进行常规左甲状腺素治疗,对TSH低于10.0 mIU/L的患者进行个体化治疗。